皓宸医疗(002622) - 2021 Q2 - 季度财报

Financial Performance - The company's operating revenue for the first half of 2021 was ¥49,098,637.57, representing a 65.69% increase compared to ¥29,632,396.01 in the same period last year[19]. - The net profit attributable to shareholders was ¥9,261,137.11, a significant turnaround from a loss of ¥32,419,460.31 in the previous year, marking a 128.57% improvement[19]. - The net profit after deducting non-recurring gains and losses was ¥8,346,837.84, compared to a loss of ¥33,835,256.29 in the same period last year, reflecting a 124.67% increase[19]. - The basic earnings per share increased to ¥0.0110 from a loss of ¥0.0386, showing a 128.50% improvement[19]. - The total operating revenue for the first half of 2021 reached ¥49,098,637.57, a significant increase of 65.6% compared to ¥29,632,396.01 in the same period of 2020[136]. - The company reported a net profit of ¥9,261,137.11 for the first half of 2021, a turnaround from a net loss of ¥32,419,460.31 in the first half of 2020[138]. - The total comprehensive income for the first half of 2021 was ¥20,166,731.97, a significant recovery from a loss of ¥28,851,587.81 in the previous year[139]. - The company reported a net loss of approximately RMB 8.21 million for the first half of 2021, indicating a significant decline in profitability[163]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,401,582,549.01, up 4.55% from ¥1,340,539,193.47 at the end of the previous year[19]. - The total liabilities increased to CNY 510,007,955.13 from CNY 469,476,440.14, reflecting a rise of about 8.6%[130]. - The company's total equity at the end of the reporting period was 1,246,920.90 yuan, down from 1,284,000.00 yuan at the beginning of the period, indicating a reduction of approximately 2.9%[156]. - The total liabilities at the end of the current period were not specified, indicating a need for further financial clarity[160]. Cash Flow - The net cash flow from operating activities was ¥5,461,770.60, a decrease of 53.63% compared to ¥11,779,170.25 in the same period last year[19]. - The cash flow from operating activities was ¥46,512,302.47, compared to ¥54,557,946.14 in the first half of 2020, indicating a decrease in cash inflow from operations[145]. - The total cash inflow from investment activities was ¥45,000,000.00, compared to ¥64,048,993.15 in the previous year, reflecting a decline of 29.8%[147]. - The cash outflow for debt repayment was ¥7,000,000.00, a decrease from ¥80,586,946.35 in the previous year, indicating a reduction in debt servicing[147]. Investments and Acquisitions - The company plans to acquire control of Guangzhou Delun Medical Investment Co., Ltd. through a cash payment, as approved in the board meetings held on May 27, 2021[5]. - The company holds a 7.39% stake in Fushun Bank, valued at 607,698,687.78 RMB, with a market value of 22,700,000 shares[52]. - The total profit from investment activities was ¥24,843,081.04, accounting for 257.43% of total profit, indicating a strong performance from the investment in Fushun Bank[43]. Operational Highlights - The company primarily engages in the research, production, and sales of permanent magnet switches and high/low voltage switchgear, along with software development and leasing of office space[27]. - The subsidiary Jilin Yongda Electric has established a marketing network covering over 20 provinces, providing comprehensive services including pre-sale, in-sale, and after-sale support[27]. - Yongda Electric has upgraded its products to meet the requirements of the national smart grid, enhancing features such as fault judgment, recording, and network interaction[27]. - The company has made breakthroughs in the electric furnace and chemical industries, focusing on project stability and success rates to drive overall performance growth[28]. Research and Development - Research and development expenses increased to ¥4,061,809.26, up from ¥3,825,219.23, indicating a focus on innovation[136]. - The company emphasizes a customer and market-driven approach in its R&D innovation system, ensuring continuous technological progress[33]. - The company has accumulated nearly 100 proprietary software products and has received multiple provincial and municipal technology advancement awards[33]. Corporate Governance and Compliance - The company has no significant environmental violations and complies with environmental protection regulations, with no penalties reported during the period[70]. - The integrity status of the company and its major shareholders is reported to be good during the reporting period[82]. - There were no related party transactions in daily operations during the reporting period[83]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 71,259[113]. - Guangzhou Huiyin Rifen Investment Partnership holds 23.81% of the shares, totaling 200,000,000 common shares[114]. - The second largest shareholder, Shaanxi International Trust Co., Ltd., holds 3.84% with 32,263,200 common shares[115]. Financial Reporting and Standards - The semi-annual financial report has not been audited[126]. - The financial statements are prepared in RMB[127]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring accurate financial reporting[174].